Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Limertinib Plus Platinum-Based Chemotherapy in EGFR-Mutated NSCLC After EGFR-TKI Progression
ChiCTR2500114831Phase 2Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of limertinib in Non-small cell lung cancer (NS-NSCLC), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Progression-free survival. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
limertinib
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on ChiCTR2500114831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114831.